Comparing Clinical Effectiveness and Drug Toxicity With Hydrochlorothiazide and Chlorthalidone Using Two Potency Ratios in a Managed Care Population

Journal of Clinical Hypertension

Volumn 17, Issue 2, 2015, Pages 134-140

  Saseen, Joseph J ^a,b   Ghushchyan, Vahram ^a   Nair, Kavita V ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORTALIDONE; HYDROCHLOROTHIAZIDE; POTASSIUM; ANTIHYPERTENSIVE AGENT;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; DIASTOLIC BLOOD PRESSURE; DRUG POTENCY; DRUG TOXICITY; ELECTRONIC MEDICAL RECORD; FEMALE; HEALTH INSURANCE; HUMAN; HYPERTENSION; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; MEAN ARTERIAL PRESSURE; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; UNITED STATES; BLOOD PRESSURE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SYSTOLE; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHLORTHALIDONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; RETROSPECTIVE STUDIES; SYSTOLE; TREATMENT OUTCOME; UNITED STATES;

EID: 84923014728     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12453     Document Type: Article

References (27)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-e245.
2. Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med. 2009;361:2153-2164.
3. Kaplan NM. Chlorthalidone versus hydrochlorothiazide: a tale of tortoises and a hare. Hypertension. 2011;58:994-995.
4. Cranston WI, Juel-Jensen BE, Semmence AM, et al. Effects of oral diuretics on raised arterial pressure. Lancet. 1963;2:966-970.
5. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616-1628.
6. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
7. Rosei EA, Dal Palu C, Leonetti G, et al. Clinical results of the Verapamil inHypertension and Atherosclerosis Study. VHAS Investigators. J Hypertens. 1997;15:1337-1344.
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
9. Dorsch MP, Gillespie BW, Erickson SR, et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57:689-694.
10. National Clinical Guideline Centre. Hypertension - The clinical management of primary hypertension in adults. Clinical Guideline 127: Methods, evidence, and recommendations. August 2011. The Royal College of Physicians, 11 St Andrews Place, Regents Park, London, NW1 4BT.
11. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43:4-9.
12. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510-e526.
13. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
14. Leuven E, Sianesi B. SMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. Available at: http://ideas.repec.org/c/boc/bocode/s432001.html. Accessed on June 30, 2014.
15. Chronic Condition Indicator (CCI) for ICD-9-CM. Available at: https://www.hcup-us.ahrq.gov/toolssoftware/chronic/chronic.jsp. Accessed on June 30, 2014.
16. Gu Q, Dillon CF, Burt VL, Gillum RF. Association of hypertension treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertension. Am J Hypertens. 2010;23:38-45.
17. Rosendorff C. Hypertension and coronary artery disease: a summary of the American Heart Association scientific statement. J Clin Hypertension. 2007;9:790-795.
18. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
19. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16:14-26.
20. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520.
21. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219.
22. Hackam DG, Quinn RR, Ravani P, et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2013;29:528-542.
23. Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of hypertension-United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep. 2011;60:103-108.
24. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352-358.
25. Ernst ME, Carter BL, Zheng S, Grimm RH Jr. Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am J Hypertens. 2010;23:440-446.
26. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension. 2012;59:1104-1109.
27. Messerli FH, Makani H, Benjo A, et al. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol. 2011;57:590-600.